Analyst Downgrades – Regulus Therapeutics (NASDAQ:RGLS) Stock Gets Downgraded By Chardan Capital from Buy to Neutral

ME Staff
-
0

Analyst Ratings For Regulus Therapeutics (NASDAQ:RGLS)

Today, Regulus Therapeutics (NASDAQ:RGLS) stock was downgraded by Chardan Capital from Buy to Neutral.

There are 5 hold ratings, 1 buy rating on the stock.

The current consensus rating on Regulus Therapeutics (NASDAQ:RGLS) is Hold (Score: 2.17) with a consensus target price of $4.50 per share, a potential 341.18% upside.

Some recent analyst ratings include

  • 8/2/2017-Chardan Capital was Downgraded by analysts at Chardan Capital from a “Buy ” rating to a ” Neutral” rating.
  • 6/13/2017-Wedbush Reiterated Rating of Ourperform.
  • 3/3/2017-Cowen and Company Reiterated Rating of Hold.
  • 1/30/2017-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Buy ” rating to a ” Hold” rating.
  • 1/30/2017-Wells Fargo & Company was Downgraded by analysts at Wells Fargo & Company from a “Outperform ” rating to a ” Market Perform” rating.

Recent Insider Trading Activity For Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics (NASDAQ:RGLS) has insider ownership of 4.80% and institutional ownership of 38.53%.

  • On 7/25/2017 Daniel R Chevallard, CFO, bought 54,945 with an average share price of $0.91 per share and the total transaction amounting to $49,999.95. View SEC Filing
  • On 7/25/2017 Joseph P Hagan, Insider, bought 219,780 with an average share price of $0.91 per share and the total transaction amounting to $199,999.80. View SEC Filing
  • On 7/25/2017 William H Rastetter, Director, bought 274,725 with an average share price of $0.91 per share and the total transaction amounting to $249,999.75. View SEC Filing
  • On 3/22/2017 Stelios Papadopoulos, Director, bought 500,000 with an average share price of $1.22 per share and the total transaction amounting to $610,000.00. View SEC Filing
  • On 3/7/2017 William H Rastetter, Director, bought 250,000 with an average share price of $1.15 per share and the total transaction amounting to $287,500.00. View SEC Filing
  • On 3/3/2016 Joseph P Hagan, COO, bought 10,000 with an average share price of $7.19 per share and the total transaction amounting to $71,900.00. View SEC Filing
  • On 2/23/2016 Alnylam Pharmaceuticals, Inc., Major Shareholder, sold 1,000,000 with an average share price of $7.18 per share and the total transaction amounting to $7,180,000.00. View SEC Filing

Recent Trading Activity for Regulus Therapeutics (NASDAQ:RGLS)
Shares of Regulus Therapeutics closed the previous trading session at 1.02 down -0.03 -2.86% with 636,838 shares trading hands.